PT  - JOURNAL ARTICLE
AU  - Zhu, Na
AU  - LeDuc, Charles A.
AU  - Fennoy, Ilene
AU  - Laferrère, Blandine
AU  - Doege, Claudia A.
AU  - Shen, Yufeng
AU  - Chung, Wendy K.
AU  - Leibel, Rudolph L.
TI  - Predicted loss of function alleles in Bassoon (BSN) are associated with obesity
AID  - 10.1101/2023.02.19.23285978
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.19.23285978
4099  - http://medrxiv.org/content/early/2023/02/23/2023.02.19.23285978.short
4100  - http://medrxiv.org/content/early/2023/02/23/2023.02.19.23285978.full
AB  - Bassoon (BSN) is a component of a hetero-dimeric presynaptic cytomatrix protein that orchestrates neurotransmitter release with Piccolo (PCLO) from glutamatergic neurons throughout the brain. Heterozygous missense variants in BSN have previously been associated with neurodegenerative disorders in humans. We performed an exome-wide association analysis of ultra-rare variants in about 140,000 unrelated individuals from the UK Biobank to search for new genes associated with obesity. We found that rare heterozygous predicted loss of function (pLoF) variants in BSN are associated with higher BMI with log10-p value of 11.78 in the UK biobank cohort. The association was replicated in the All of Us whole genome sequencing data. Additionally, we have identified two individuals (one of whom has a de novo variant) with a heterozygous pLoF variant in a cohort of early onset or extreme obesity at Columbia University. Like the individuals identified in the UKBB and All of us Cohorts, these individuals have no history of neurobehavioral or cognitive disability. Heterozygosity for pLoF BSN variants constitutes a new etiology for obesity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH grant NIDDK 52431 and the NY Nutrition and Obesity Research Center: P30DK26685.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were under the auspices of the Columbia University IRB "Molecular Genetic Analysis of Obesity and Non-Insulin Dependent Diabetes Mellitus" IRB #: AAAA4485 which expires on 5/1/23.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors